GT Biopharma, Inc. GTBP announced on Monday that it successfully completed the dosage in cohort 1 and started dosing in cohort 2 of his phase 1 dose of escalation study for GTB-3650. The therapy is a trike-therapeutic targeting of the second generation, refunded or refractory CD33-to expression hematological malignancies. GT Biopharma specializes in immuno-oncology therapies […]
